Kiratli H, Koç I, Söylemezoğlu F
Service d'ophtalmologie, hôpitaux universitaires, université de Hacettepe, Ankara, Turquie.
Service d'ophtalmologie, hôpitaux universitaires, université de Hacettepe, Ankara, Turquie.
J Fr Ophtalmol. 2020 Nov;43(9):851-857. doi: 10.1016/j.jfo.2019.11.045. Epub 2020 Aug 20.
To report treatment outcomes of orbital tumors associated with Erdheim-Chester disease and to highlight the importance of systemic work-up in patients presenting with bilateral proptosis.
Three patients with Erdheim-Chester disease, whose initial manifestation was bilateral proptosis, were retrospectively studied. The course of onset, clinical, imaging and histopathological features, systemic associations and response to treatment were reviewed. The main outcome measures were Hertel measurements and orbital tumor regression on imaging studies.
All patients presented with bilateral non-pulsatile proptosis resistant to retropulsion and headeache without specific localization. Magnetic resonance imaging studies showed bilateral intraconal orbital tumors. Incisional biopsy of these tumors demonstrated CD68+, CD1a-, and S100- histiocytic infiltrates consistent with the diagnosis of Erdheim-Chester disease. The BRAFV600E mutation was found in all cases. Systemic work-up revealed asymptomatic bony involvement in the lower extremities, perirenal fibrosis, central nervous system and cardiac involvement. All patients initially received pegylated interferon-α2a, which resulted in excellent responses except for the orbital tumors. Two patients were then treated with vemurafenib, which resulted in rapid regression of the orbital lesions.
Pegylated interferon-α was highly effective in the control of cardiac, perirenal, skeletal and cerebral involvement but not the orbital tumors. The infiltrative orbital lesions of Erdheim-Chester disease would appear more responsive to vemurafenib.
报告与厄尔海姆-切斯特病相关的眼眶肿瘤的治疗结果,并强调对双侧眼球突出患者进行全面系统检查的重要性。
对3例最初表现为双侧眼球突出的厄尔海姆-切斯特病患者进行回顾性研究。回顾了发病过程、临床、影像学和组织病理学特征、全身关联情况及治疗反应。主要观察指标为赫特尔测量值和影像学研究中眼眶肿瘤的消退情况。
所有患者均表现为双侧非搏动性眼球突出,对眼球后推压抵抗,伴有无特定定位的头痛。磁共振成像研究显示双侧眶内圆锥肿瘤。这些肿瘤的切开活检显示CD68+、CD1a-和S100-组织细胞浸润,符合厄尔海姆-切斯特病的诊断。所有病例均发现BRAFV600E突变。全面系统检查发现下肢无症状性骨质受累、肾周纤维化、中枢神经系统和心脏受累。所有患者最初接受聚乙二醇化干扰素-α2a治疗,除眼眶肿瘤外,均取得了良好反应。随后,2例患者接受维莫非尼治疗,眼眶病变迅速消退。
聚乙二醇化干扰素-α在控制心脏、肾周、骨骼和脑部受累方面非常有效,但对眼眶肿瘤无效。厄尔海姆-切斯特病的浸润性眼眶病变对维莫非尼似乎更敏感。